In 2022 and 2023, following a long period of low interest rates, the US Fed fought the post-pandemic inflation shock with one of the most rapid rate-hiking cycles in history.
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...